Core business is expected to do extremely well given the impact...

Core business is expected to do extremely well given the impact of the direction of the new MD who has focused on getting sales people
and partnership arrangements deployed since commencement of his tenure. From the last AGM and other discussions : China, Europe (who have mandated increased DHA levels in baby formulae by 2020) and USA (where Martek is about to be out of patent) are expected to do rather well. The stock is closely held amongst the top 5 shareholders ( for disclosure I am in this group) hence if you want big parcels you will need to quote big. Also the trials re pre term babies is not seen as a total failure as only one indicator failed to meet the standards..other test criteria will be investigated. The stock is debt free, conservatively managed and has unique (patented) processes in micro capsulation, and pays fully franked dividends ..it is my mini blue chip stock in my portfolio